# Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

> **NCT06623110** · PHASE2 · RECRUITING · sponsor: **Glenn J. Hanna** · enrollment: 25 (estimated)

## Conditions studied

- High-Risk Oral Precancerous Disease

## Interventions

- **BIOLOGICAL:** RP2 Injection

## Key facts

- **NCT ID:** NCT06623110
- **Lead sponsor:** Glenn J. Hanna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06623110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06623110, "Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06623110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*